Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.EU approves Pfizer Vyndaqel for TTR-FAP
Vyndaqel is a transthyretin stabilizer which prevents the formation of misfolded proteins and the subsequent amyloid deposits that lead to neurodegeneration and decline of neurologic function. A pivotal
Vyndaqel is a transthyretin stabilizer which prevents the formation of misfolded proteins and the subsequent amyloid deposits that lead to neurodegeneration and decline of neurologic function. A pivotal
The deal covers Mobile Intelligence Key Account Management (KAM), Key Opinion Leader (KOL) and Configuration and Administration Tools. It also includes OneKey, the healthcare professional database; help desk
The software is believed to aid in pharmaceutical actions, generate efficiencies in stock management and dispensing processes, provide the required information to implement performance and risk management. In
Imipenem-cilastatin, a generic version of Merck’s Primaxin is a carbapenem that belongs to the beta-lactam class of antibiotics. The medication will be made available in 250 mg and
The company will produce ADI-PEG 20 products and targets an annual production value of around $2bn, news.cens.com reported. Polaris developed ADI-PEG 20 drug for the treatment of cancers.
Martino served at a cancer therapeutics company – Sonus Pharmaceuticals as president and CEO from 1999 to 2008 where he developed company’s lead cancer therapeutic through a pivotal
The study involved 132,000 patients who were placed into categories to compare levels of vitamin D: low (less than 20 nanograms per decilter), low/normal (21-40 ng/dl), normal (41-80
Cenix conducts contract research and develops technology for RNA interference (RNAi), miRNA modulation and high content phenotyping to accelerate target discovery, target validation, and the non-clinical development of
Biosimilars are drugs whose effects are similar to those of biopharmaceuticals and are sold by a different manufacturer once the original drugs’ patent expires, pharmalive.com reported. The joint
Under the agreement, both the companies will boost the clinical development besides increasing productivity and cost effectiveness. UCB will receive the benefits of PAREXEL’s clinical processes through all